
News|Articles|February 1, 2010
FDA Pipeline preview, February 2010 (Ceftobiprole, Carglumic acid, Miglustat, Nebivolol, Myocet, Pirfenidone, Davunetide, BiovaxID, EpiCept, CP-4126)
Recent FDA action (through February 2010) related to Ceftobiprole, Carglumic acid, Miglustat, Nebivolol, Myocet, Pirfenidone, Davunetide, BiovaxID, EpiCept, CP-4126
Advertisement
Complete response
Recommended for approval
Not recommended for approval
Priority review
Orphan drug designation
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Transplant-fueled hybrid immune systems may help reverse Type 1 diabetes
2
ACIP to vote on major hepatitis B vaccine update that could reshape the childhood vaccine schedule
3
New test may solve the specificity and false-positive problems of the PSA test for prostate cancer
4
ACIP votes to end universal birth-dose for hepatitis B vaccine with updated guidance for parents and doctors
5






















































